The Teva-Lonza Joint Venture issued the following statement today:

The potential to develop, manufacture and market affordable, efficacious and safe biosimilars remains an area of significant opportunity for both Teva and Lonza.

There is significant regulatory uncertainty in the biosimilars arena at present. Therefore, both companies are taking a measured approach, choosing to fully evaluate the prevailing regulatory and commercial circumstances before agreeing on further long-term investment decisions that both partners are comfortable with.